Early termination of antidepressant drug treatment

Journal of Clinical Psychopharmacology

Volumn 20, Issue 5, 2000, Pages 523-530

  Linden, Michael ^a   Gothe, Holger ^a   Dittmann, Ralf W ^b,c   Schaaf, Berthold ^d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d Factum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE;

ARTICLE; CHRONICITY; DEPRESSION; DRUG USE; DRUG WITHDRAWAL; GENERAL PRACTICE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; FAMILY PRACTICE; FEMALE; FLUOXETINE; GERMANY; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PROGNOSIS; PSYCHIATRY; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 0033829614     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200010000-00005     Document Type: Article

References (78)

1. Depressive relapses and incomplete recovery from index episode
2. Mood disorders: Pharmacologic prevention of recurrences
3. A plea for the 'naturalistic' study of medicines
4. Duration of antidepressant drug treatment: What is an adequate trial?
5. Methodological issues in maintenance therapy clinical trials
6. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process
7. Die Phase IV der therapie-evaluation
8. Phase IV research and drug utilization observation studies
9. Fluoxetin: Ergebnisse einer anwendungsbeobachtung
10. Depression: Treatment compliance in general practice
11. Implications of noncompliance on research in affective disorders
12. Out-patient compliance with antidepressant medication
13. Definition and epidemiology of treatment-resistant depression
14. Continuation drug therapy for major depressive episodes: How long should it be maintained?
15. The definition and operational criteria for treatment outcome of major depressive disorder: A review of the current research literature
16. Faktoren der chronifizierung von depressionen
17. The cost of drug therapy failure: A study of antidepressant use patterns in a Medicaid population
18. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder
19. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication
20. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
21. Three types of early termination of antidepressant drug treatment
22. Fluoxetin in der anwendung durch niedergelassene nervenarzte
23. Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy
24. An investigation of the representativity of neuropsychiatrists and their patients in a drug utilization observation study on fluoxetine
25. Investigation of epidemiological representativity exemplified in a comprehensive case surveillance (Anwendungsbeobachtung)
26. The new generation of antidepressants
27. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder
28. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder
29. Clinical pharmacology and pharmacokinetics of fluoxetine: A review
30. The safety of fluoxetine: An update
31. Fluoxetine efficacy against placebo and by dose: An overview
32. Fluoxetine efficacy vs. comparative drugs: An overview
33. Fluoxetine vs. amitriptyline in the treatment of depressed out-patients
34. The prophylactic efficacy of fluoxetine in unipolar depression
35. Safety of fluoxetine: Comparison with fluvoxamine
36. Fluoxetine, a highly selective serotonin reuptake inhibitor: A review of preclinical studies
37. Effect of fluoxetine on the electrocardiogram
38. Therapieresistenz und patienten-non-compliance bei depressiven storungen
39. Antidepressant drugs: Side effects and compliance
40. Time course of improvement under antidepressant treatment: A survival-analytic approach
41. How long to onset of antidepressant action: A meta-analysis of patients treated with fluoxetine or placebo
42. Dysthymic disorder: Psychopathology of proposed chronic depressive subtypes
43. Short-term, subchronic, and chronic sequelae of affective disorders
44. 'Double depression': Two-year follow-up
45. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: A prospective follow-up
46. Relapse in recurrent unipolar depression
47. The minimum length of treatment for recovery
48. Early recurrence in unipolar depression
49. Three-year outcomes for maintenance therapies in recurrent depression
50. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence
51. Maintenance therapy of depression
52. Life events, depressive relapse and maintenance treatment
53. Imipramine with electrical treatment in depression: A controlled trial
54. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness
55. Lithium carbonate and imipramine in prevention of affective episodes
56. Treatment of depression by drugs and psychotherapy
57. How long should prophylactics be continued in affective disorders?
58. Prophylaxis of affective disorders: Current status of knowledge
59. Continuation therapy with amitriptyline in depression
60. Maintenance therapy with amitriptyline: A controlled trial
61. Relapse in affective disorders: A reanalysis of the literature using life table methods
62. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination
63. Can patients' views of the therapeutic system predict outcome? An empirical study with depressive patients
64. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
65. Therapieresistenz auf antidepressiva. Risikofaktoren und behandlungsmoglichkeiten
66. Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed patients
67. Verlaufskontrolle und erfolgsbeurteilung der arzneimitteltherapie
68. Adequate treatment with imipramine in continuation treatment
69. Die kombination verschiedener antidepressiva in der behandlung therapieresistenter depressionen
70. Residual symptoms in depressed patients who respond acutely to fluoxetine
71. Management options for refractory depression
72. Declaration of treatment failures
73. Die bedeutung der zeit fur die therapie depressiver syndrome in der ambulanten praxis
74. Antidepressiva-langzeitmedikation
75. Die behandlung mit antidepressiva in der praxis des niedergelassenen arztes
76. Gesamtbehandlungsplan bei depressiven erkrankungen - Grundsatze der ambulanten depressionstherapie